TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $473,103 | -13.8% | 30,801 | +26.2% | 0.02% | -17.9% |
| Q1 2023 | $549,003 | +2.9% | 24,411 | -3.7% | 0.03% | 0.0% |
| Q4 2022 | $533,321 | +10.9% | 25,360 | +30.0% | 0.03% | +3.7% |
| Q3 2022 | $481,000 | -2.6% | 19,510 | -4.3% | 0.03% | +8.0% |
| Q2 2022 | $494,000 | -8.2% | 20,386 | -2.3% | 0.02% | 0.0% |
| Q1 2022 | $538,000 | -17.6% | 20,875 | -0.8% | 0.02% | -10.7% |
| Q4 2021 | $653,000 | +15.0% | 21,048 | -10.1% | 0.03% | +7.7% |
| Q3 2021 | $568,000 | – | 23,412 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |